The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
An overview of FDA-approved new molecular entities: 1827–2013
Abstract
The pharmaceutical industry is undergoing fundamental change and its future is unclear. We performed a meta-analysis by cataloging FDA-approved legacy drugs and new molecular entities (NMEs). Objective information regarding scientific, medical and commercial activities was captured and provides insight into processes governing drug development. In this report, we review the rates of NME introduction through to the end of 2013. Recent trends show the emergence of a handful of companies that controls two-thirds of NMEs. We also report growth in the number of NMEs controlled by marketing organizations that have little or no internal drug discovery or development activities. This trend has increased dramatically since 2000 and could raise important questions about the future landscape and viability of drug discovery and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By comparison, development of new classes of drugs for the treatment of hypertension has remained steady over the same time period18 (Fig. 1).”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [18]
In the citing paper
“Since the 1950s, new molecular entities approved by the US Food and Drug Administration (FDA) with primary indications for anxiety have been limited to benzodiazepines and the atypical anxiolytics buspirone, meprobamate and hydroxyzine pamoate18.”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [18]
Citations
Cites
Deconstructing the Drug Development Process: The New Face of Innovation
Kaitin, K. I. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.293 · Cited by 419
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 332
Overview of the Hatch-Waxman Act and its impact on the drug development process.
Gj, M. (1999) · PubMed · Cited by 133
Aspirin: The Remarkable Story of a Wonder Drug
Jeffreys, D. (2004) · Cited by 83
Stelzer, W., Aiglesberger, M., Stelzer, D., & Stelzer, V. (2012) · Pain Medicine · doi:10.1111/pme.12014 · Cited by 71
COX-2 Inhibition: What We Learned—A Controversial Update on Safety Data
Katz, J. A. (2013) · Pain Medicine · doi:10.1111/pme.12252 · Cited by 38
Historical milestones and discoveries that shaped the toxicology sciences
Hayes, A., & Gilbert, S. G. (2009) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-7643-8336-7_1 · Cited by 27
Flagged first, then by citations
Research works printed but not linked: 1
- GlaxoSmithKline Press release, 2014
Cited by
Sorted by citations
Items 201–211 of 211
Frauengesundheit – Frauenmedizin
(2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23571-9.09981-8
4.2.3.9. Synthesis of π-Conjugated Systems Using Formylchromone as Building Block
Fernandes, C., Oliveira, C., Borges, F., & Gaspar, A. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781849739634-00399
Roller, S. (2023) · doi:10.33612/diss.663386097
Primorac, D., Bach‐Rojecky, L., Brlek, P., & Škaro, V. (2023) · Springer eBooks · doi:10.1007/978-3-031-45903-0_17
Ali, R., Al-Tamimi, E. O., & Alrecabi, Z. G. (2024) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428024040201
Lanshoeft, C. (2017) · theses.fr (ABES) · doi:10.70675/70955a37z9a6cz40f5zbe72z9049aa84a7f0
Shaikh, F., Suvarna, V., & Mallya, R. (2026) · Current Indian Science · doi:10.2174/012210299x399484251125114642
Analysis of FDA approvals, delays and denials of new drug applications, 2013–2023
McCarthy, G., & O’Boyle, N. M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104739
Metadata
- Authors
- Kinch, M. S., Haynesworth, A., Kinch, S. L., & Hoyer, D.
- Affiliations
- Yale University (US)
- Corresponding author
- Kinch, Michael S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 19
- Issue
- 8
- Pages
- 1033-1039
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2046088696
- Cited by
- 210
- References
- 7
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 17 · 2022: 12 · 2021: 15 · 2020: 22 · 2019: 24 · 2018: 25 · 2017: 28 · 2016: 22 · 2015: 22 · 2014: 8
- FWCI
- 66.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Firm Innovation and Growth
- Keywords
- new chemical entities, FDA-approved drugs, drug development trends, pharmaceutical industry consolidation, drug discovery, pharmaceutical companies, marketing organization, drug approval rates
- MeSH terms
- Drug Industry, Time Factors, United States, United States Food and Drug Administration, Drug Approval, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
